Advertisement

World Journal of Pediatrics

, Volume 14, Issue 5, pp 437–447 | Cite as

Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition)

  • Xing-Wang Li
  • Xin Ni
  • Su-Yun Qian
  • Quan Wang
  • Rong-Meng Jiang
  • Wen-Bo Xu
  • Yu-Cai Zhang
  • Guang-Jun Yu
  • Qiang Chen
  • Yun-Xiao Shang
  • Cheng-Song Zhao
  • Hui Yu
  • Ting Zhang
  • Gang Liu
  • Hui-Ling Deng
  • Jie Gao
  • Xian-Gui Ran
  • Qiao-Zhi Yang
  • Bian-Li Xu
  • Xue-Yong Huang
  • Xing-Dong Wu
  • Yi-Xiao Bao
  • Yi-Ping Chen
  • Zhi-Hai Chen
  • Qing-Quan Liu
  • Guo-Ping Lu
  • Chun-Feng Liu
  • Rong-Bing Wang
  • Guo-Liang Zhang
  • Fang Gu
  • Hong-Mei Xu
  • Ying Li
  • Tao Yang
Review Article
  • 61 Downloads

Abstract

Background

Hand, foot, and mouth disease (HFMD) is a common infectious disease in childhood caused by an enterovirus (EV), and which is principally seen in children under 5 years of age. To promote diagnostic awareness and effective treatments, to further standardize and strengthen the clinical management and to reduce the mortality of HFMD, the guidelines for diagnosis and treatment have been developed.

Methods

National Health Commission of China assembled an expert committee for a revision of the guidelines. The committee included 33 members who are specialized in diagnosis and treatment of HFMD.

Results

Early recognition of severe cases is utmost important in diagnosis and treatment of patients with HFMD. The key to diagnosis and treatment of severe cases lies in the timely and accurate recognition of stages 2 and 3 of HFMD, in order to stop progression to stage 4. Clinicians should particularly pay attention to those EV-A71 cases in children aged less than 3 years, and those with disease duration less than 3 days. The following indicators should alert the clinician of possible deterioration and impending critical disease: (1) persistent hyperthermia; (2) involvement of nervous system; (3) worsening respiratory rate and rhythm; (4) circulatory dysfunction; (5) elevated peripheral WBC count; (6) elevated blood glucose and (7) elevated blood lactic acid. For treatment, most mild cases can be treated as outpatients. Patients should be isolated to avoid cross-infection. Intense treatment modalities should be given for those severe cases.

Conclusion

The guidelines can provide systematic guidance on the diagnosis and management of HFMD.

Keywords

Diagnosis Guidelines HFMD Treatment 

Notes

Acknowledgements

The Chinese version of this Guideline was published in the June issue of Chin J Infect Dis in 2018. We acknowledge the editing assistance of the English version of HFMD guidelines from Stephen Toovey, MD, PhD, and Jim Wu PhD, and also thank Mi Yao and Zhi-Jie Xu for translation support.

Author contributions

LXW, NX, QSY: contributed equally to this guideline. All the other authors confirmed the final version of the guideline.

Funding

The National Clinical Key Department of Infectious Diseases; The Key Medical Specialty Program of Sailing Plans organized by Beijing Municipal Administration of Hospitals (No. ZYLX201602)

Compliance with ethical standards

Ethical approval

Not required.

Conflict of interest

No financial or nonfinancial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.

References

  1. 1.
    Zhang SB, Liao H, Huang CH, Tan QY, Zhang WL, Huang Y, et al. Serum types of enterovirus and clinical characteristics of 237 children with hand, foot and mouth disease in Shenzhen. Chin J Contemp Pediatr. 2008;10:38–41 (in Chinese).Google Scholar
  2. 2.
    Song Y, Zhang Y, Ji T, Gu X, Yang Q, Zhu S, et al. Persistent circulation of Coxsackievirus A6 of genotype D3 in mainland of China between 2008 and 2015. Sci Rep. 2017;7:5491 (in Chinese)CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Tan XJ, Huang XY, Zhu SL, Chen H, Yu QL, Wang HY, et al. The persistent circulation of enterovirus 71 in People’s Republic of China: causing emerging nationwide epidemics since 2008. PLoS One. 2011;6:e25662.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Zhou HT. Epidemiological and clinical characteristics of hand, foot and mouth disease in Guangdong Province during 2009–2013. South Med Univ. 2014.Google Scholar
  5. 5.
    Yang YP, Chen MM, Ju Y, Wang J, Huang J, Tan Y. Epidemiology and pathogen distribution of hand-foot-mouth disease in Guangxi, 2008–2014. Appl Prev Med. 2015;21:365–8.Google Scholar
  6. 6.
    Chen GP, Shi YL, Zhang J, Cao MH, Wu JB, Hu WF, et al. Analysis of the epidemiological characteristics of hand-foot-and-mouth disease in Anhui Province between 2008 and 2014. Mod Prev Med. 2016;43:588–90.Google Scholar
  7. 7.
    Bo YC, Song C, Wang JF, Li XW. Using an autologistic regression model to identify spatial risk factors and spatial risk patterns of hand, foot and mouth disease (HFMD) in Mainland China. BMC Public Health. 2014;14:1–13.CrossRefGoogle Scholar
  8. 8.
    Zhang C. The study of epidemiology and influencing factors of hand, foot and mouth disease in Guangxi Province from, 2008 to 2015. Guangxi Med Univ J. 2016:1–69 (in Chinese).Google Scholar
  9. 9.
    Zhao J, Jiang F, Zhong L, Sun J, Ding J. Age patterns and transmission characteristics of hand, foot and mouth disease in China. BMC Infect Dis. 2016;16:691. CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Yu P, Bao L, Xu L, Li F, Lv Q, Deng W, et al. Neurotropism in vitro and mouse models of severe and mild infection with clinical strains of enterovirus 71. Viruses. 2017;9:351. CrossRefGoogle Scholar
  11. 11.
    Xing J, Liu D, Shen S, Su Z, Zhang L, Duan Y, et al. Pathologic studies of fatal encephalomyelitis in children caused by enterovirus 71. Am J Clin Pathol. 2016;146:95–106.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Wu J, Cheng YB, Li ZF, Li YF, Li YP, Xu HM, et al. Evaluation of adrenocortical function in children with severe and critical enterovirus 71 infection. Chin J Pediatr. 2012;50:249–54 (in Chinese)Google Scholar
  13. 13.
    Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, Lei HY. A murine oral enterovirus 71 infection model with central nervous system involvement. J Gen Virol. 2004;85:69–77.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778–90.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Yan JJ, Wang JR, Liu CC, Yang HB, Su IJ. An outbreak of enterovirus 71 infection in Taiwan 1998: a comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. J Clin Virol. 2000;17:13–22. CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Hu J, Shi XH, Tang Y, Ge XH, Yu Y, Yang J, et al. Analysis of course of 94 cases of severe hand, foot and mouth disease complicated with viral meningitis encephalitis. Acta Univ Med Nanjing (Nat Sci). 2009;29:1616–8 (in Chinese).Google Scholar
  17. 17.
    Chen HI, Liao JF, Kuo L, Ho ST. Centrogenic pulmonary hemorrhagic edema induced by cerebral compression in rats. Mechanism of volume and pressure loading in the pulmonary circulation. Circ Res. 1980;47:366–73. CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Maron MB, Holcomb PH, Dawson CA, Rickaby DA, Clough AV, Linehan JH. Edema development and recovery in neurogenic pulmonary edema. J Appl Physiol. 1994;77:1155–63. CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Malik AB. Mechanisms of neurogenic pulmonary edema. Circ Res. 1985;57:1–18. CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Wu JM, Wang JN, Tsai YC, Liu CC, Huang CC, Chen YJ, et al. Cardiopulmonary manifestations of fulminant enterovirus 71 infection. Pediatrics. 2002;109:E26.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fu YC, Chi CS, Chiu YT, Hsu SL, Hwang B, Jan SL, et al. Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child. 2004;89:368–73. CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Clinical Experts Group of the Ministry of Health for Hand, Foot and Mouth Disease. Experts consensus on rescue and treatment of severe cases with enterovirus 71 (EV71) infection. Zhonghua Er Ke Za Zhi. 2011;49:675–8 (in Chinese)Google Scholar
  23. 23.
    Wang XW, Zhong TY, Tian Y. Analysis of myocardial zymogram in children with severe hand, foot and mouth disease. Med J Nat Defending Forces Southwest China. 2009;19:1001–2 (in Chinese)Google Scholar
  24. 24.
    National Health and Family Planning Commission of the People's Republic of China. Guideline for the diagnosis and treatment of hand, foot and mouth disease (2010 Edition). http://www.nhfpc.gov.cn/yzygj/s3593g/201306/6d935c0f43cd4a1fb46f8f71acf8e245.shtml. Accessed 15 Apr 2017.
  25. 25.
    Gmitterová K, Heinemann U, Krasnianski A, Gawinecka J, Zerr I. Cerebrospinal fluid markers in the differentiation of molecular subtypes of sporadic Creutzfeldt-Jakob disease. Eur J Neurol. 2016;23:1126–33. CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Wu YD, Shang SQ, Chen ZM, Yang ZH. Analysis of the epidemic characteristics of the etiological agents in children with hand, foot and mouth disease and its clinical significance. Zhonghua Er Ke Za Zhi. 2010;48:535–9 (in Chinese)PubMedPubMedCentralGoogle Scholar
  27. 27.
    Jin L, Huang XM. HFMD rash and the identification. Med Recapitulate. 2012;18:1680–3. Google Scholar
  28. 28.
    Wang J, Campbell IL, Zhang H. Systemic interferon-a regulates interferon-stimulated genes in the central nervous system. Mol Psychiatry. 2008;13:293–301. CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Qiu J, Lu XL, Liu X, Zhang P, Zhao W, Liu P, et al. Derivation and validation of a mortality risk score for severe hand, foot and mouth disease in China. Sci Rep. 2017;7:3371. CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Lu GP. Diagnosis and treatment of neurogenic pulmonary edema in children with severe hand, foot and mouth disease. Chin Pediatr Emerg Med. 2011;18:8–10 (in Chinese)Google Scholar
  31. 31.
    Mao YY, Yao JH, Cao LF, Wang QL, Chen LH, Si MQ. Analysis of the treatment response and prognosis of severe hand-foot-mouth disease. Chin J Infect Dis. 2009;27:35–8 (in Chinese)Google Scholar
  32. 32.
    Huang T, Li QF, Shen XL, Fu XQ, Cun JP. Analysis of the risk factors for severe hand-foot-and-mouth disease (HFMD) in Yunnan Province. Mod Prev Med. 2017;44:1115–9.Google Scholar
  33. 33.
    Sasaki O, Karaki T, Imanishi J. Protective effect of interferon on infections with hand, foot, and mouth disease virus in newborn mice. J Infect Dis. 1986;153:498–502. CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Huang Y. Curative effect observation on recombinant human interferon α2b Spray in hand-foot-and-mouth disease. China Pract Med. 2014;9:47–8 (in Chinese)Google Scholar
  35. 35.
    Lin H, Huang L, Zhou J, Lin K, Wang H, Xue X, et al. Efficacy and safety of interferon-α2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial. Adv Virol. 2016;161:1–8.Google Scholar
  36. 36.
    Cao L, Zhang L, Tian L, Deng J. Antivirus effects and clinical evaluation of recombinant human interferon α2b spray. Chin Med Biotechnol. 2011;6:334–6 (in Chinese)CrossRefGoogle Scholar
  37. 37.
    Wei CH. Clinical and Virological Efficacy of Recombine Human Interferon α-2b for Hand-foot-mouth Disease in Children. Eval Anal Drug-use Hosp China. 2013;13:1018–20 (in Chinese)Google Scholar
  38. 38.
    Zong WY. Observation of the effects of adjunctive therapy of recombinant human interferon α2b Spray on hand, foot and mouth disease. Hebei Med J. 2011;33:2808–9 (in Chinese)Google Scholar
  39. 39.
    Huang X, Zhang X, Wang F, Wei H, Ma H, Sui M, et al. Clinical efficacy of therapy with recombinant human interferon α1b in hand, foot, and mouth disease with enterovirus 71 infection. PLoS One. 2016;11:e0148907.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Tan J, Wang WM, Lei KJ. Gamma globulin intravenous drip combined with interferon aerosol inhalation on severe hand, foot and mouth disease in children. J Pediatr Pharm. 2017;23:21–3.Google Scholar
  41. 41.
    Zhang XD, Tian YK, Xiong F, Mou DL, Wang W. Clinical observation of recombinant human interferon α-2b injection by aerosol inhalation in treatment of hand-foot-mouth disease of children. Drugs Clin. 2014;29:404–7 (in Chinese)Google Scholar
  42. 42.
    Zeng JS, Qian SY. Characteristics and diagnosis and treatment for severe hand foot and mouth disease. Chin J Crit Care Med. 2008;28:752–3 (in Chinese)Google Scholar
  43. 43.
    Li YL, Wang WH, Yang HR. Efficacy observation on the treatment of hand foot mouth disease by Multi-channel application of interferon α-2b. Tianjin Med J. 2013;41:78–9 (in Chinese)Google Scholar
  44. 44.
    Xu Y, Li Y, Chen Y, Xin S, Xie L, Liang Y, et al. A multicenter and contrasted clinical study on efficacy and safety of recombinant human interferon α2b spray in the treatment of hand-foot-and-mouth disease in kids. Chin J Infect Dis. 2018;36:101–7 (in Chinese).Google Scholar
  45. 45.
    Chi CY, Khanh TH, le Thoa PK, Tseng FC, Wang SM, le Thinh Q, et al. Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: a randomized controlled trial. Crit Care Med. 2013;41:1754–60.CrossRefPubMedCentralGoogle Scholar
  46. 46.
    Wang SM, Lei HY, Huang MC, Su LY, Lin HC, Yu CK, Wang JL, Liu CC. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol. 2006;37:47–52. CrossRefPubMedCentralGoogle Scholar
  47. 47.
    Ye N, Gong X, Pang LL, Gao WJ, Zhang YT, Li XL, et al. Cytokine responses and correlations thereof with clinical profiles in children with enterovirus 71 infections. BMC Infect Dis. 2015;15:225. CrossRefPubMedCentralGoogle Scholar
  48. 48.
    Zeng M, Zheng X, Wei R, Zhang N, Zhu K, Xu B, et al. The cytokine and chemokine profiles in patients with hand, foot and mouth disease of different severities in Shanghai, China, 2010. PLoS Negl Trop Dis. 2013;7:e2599.CrossRefPubMedCentralGoogle Scholar
  49. 49.
    Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–28. CrossRefPubMedCentralGoogle Scholar
  50. 50.
    Hu YM, Wang X, Wang JZ, Wang L, Zhang YJ, Chang L, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6–59 months. Clin Vaccine Immunol. 2013;12:1805–11. CrossRefGoogle Scholar
  51. 51.
    Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multi centre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–32. CrossRefPubMedCentralGoogle Scholar
  52. 52.
    Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829–37.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine 2018

Authors and Affiliations

  • Xing-Wang Li
    • 1
  • Xin Ni
    • 2
  • Su-Yun Qian
    • 3
  • Quan Wang
    • 3
  • Rong-Meng Jiang
    • 1
  • Wen-Bo Xu
    • 4
  • Yu-Cai Zhang
    • 5
  • Guang-Jun Yu
    • 6
  • Qiang Chen
    • 7
  • Yun-Xiao Shang
    • 8
  • Cheng-Song Zhao
    • 9
  • Hui Yu
    • 10
  • Ting Zhang
    • 11
  • Gang Liu
    • 9
  • Hui-Ling Deng
    • 12
  • Jie Gao
    • 13
  • Xian-Gui Ran
    • 14
  • Qiao-Zhi Yang
    • 15
  • Bian-Li Xu
    • 16
  • Xue-Yong Huang
    • 16
  • Xing-Dong Wu
    • 17
  • Yi-Xiao Bao
    • 18
  • Yi-Ping Chen
    • 19
  • Zhi-Hai Chen
    • 1
  • Qing-Quan Liu
    • 20
  • Guo-Ping Lu
    • 21
  • Chun-Feng Liu
    • 22
  • Rong-Bing Wang
    • 23
  • Guo-Liang Zhang
    • 24
  • Fang Gu
    • 25
  • Hong-Mei Xu
    • 26
  • Ying Li
    • 27
  • Tao Yang
    • 28
  1. 1.Infectious Disease Diagnosis and Treatment CenterBeijing Ditan Hospital Capital Medical UniversityBeijingChina
  2. 2.Otorhinolaryngology Head and Neck SurgeryBeijing Children’s Hospital, Capital Medical UniversityBeijingChina
  3. 3.Prediatric Intensive Care UnitBeijing Children’s Hospital of Capital Medical UniversityBeijingChina
  4. 4.National Institute For Viral Disease Control and PreventionChinese Center for Disease Control and PreventionBeijingChina
  5. 5.Pediatric Intensive Care UnitChildren’s Hospital of Shanghai Jiaotong UniversityShanghaiChina
  6. 6.Children’s Hospital of Shanghai Jiaotong UniversityShanghaiChina
  7. 7.Pneumology department, Jiangxi Provincial Children’s HospitalNanchangChina
  8. 8.Department of Pediatric PneumologyShengjing Hospital of China Medical UniversityShenyangChina
  9. 9.Department of Infectious DiseasesBeijing Children’s Hospital, Capital Medical UniversityBeijingChina
  10. 10.Department of Infectious DiseasesChildren’s Hospital of Fudan UniversityShanghaiChina
  11. 11.Digestive DepartmentChildren’s Hospital of Shanghai Jiaotong UniversityShanghaiChina
  12. 12.Department of Infectious DiseasesThe Children’s Hospital of Xi ‘anXi’anChina
  13. 13.Infection Control OfficeChildren’s Hospital of Shanghai Jiaotong UniversityShanghaiChina
  14. 14.Department of Respiratory MedicinePeople’s Hospital of Fuyang CityFuyangChina
  15. 15.Department of PediatricsPeople’s Hospital of Liaocheng CityLiaochengChina
  16. 16.Henan Provincial Center for Disease Control and PreventionZhengzhouChina
  17. 17.Department of PediatricsXiamen Maternal and Child Health Care HospitalXiamenChina
  18. 18.Pneumology DepartmentShanghai Children’s Medical Center of Shanghai Jiaotong University Medical SchoolShanghaiChina
  19. 19.Department of Pediatrics Infectious DiseasesThe Second Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina
  20. 20.Beijing Hospital of Traditional Chinese MedicineBeijingChina
  21. 21.Prediatric Intensive Care UnitChildren’s Hospital of Fudan UniversityShanghaiChina
  22. 22.Pediatric Intensive Care UnitShengjing Hospital of China Medical UniversityShenyangChina
  23. 23.Department of Integrated Traditional Chinese and Western MedicineBeijing Ditan Hospital Capital Medical UniversityBeijingChina
  24. 24.Department of Infectious DiseasesThe First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefeiChina
  25. 25.Pneumology Department, Baoding Hospital of Beijing Children’s HospitalBaodingChina
  26. 26.Department of Infectious DiseasesChildren’s Hospital of Chongqing Medical UniversityChongqingChina
  27. 27.Department of Infectious DiseasesTianjin Second People’s HospitalTianjinChina
  28. 28.Department of PediatricsYan’an Hospital of Kunming CityKunmingChina

Personalised recommendations